...remember, one of the things the FDA will have to chew on in a RYONCIL approval letter is whether to inspect lots after approval. Takes up time, requires (some) effort & costs money. Another 'belts and braces' type assay post-thaw would make it a little easier for them, I suggest, to forgo lot inspection as a condition of approval.
Just whistling in the wind.
Cheers all
Ann: FDA Notifies Clinical Data Sufficient for Refiling aGVHD BLA, page-973
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.33 |
Change
0.045(3.50%) |
Mkt cap ! $1.518B | |||
| Open | High | Low | Value | Volume |
| $1.30 | $1.35 | $1.30 | $2.885M | 2.183M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 15000 | $1.32 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.33 | 7070 | 1 |
View Market Depth
| Last trade - 16.10pm 06/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |